Biopharmaceutical company Aridis Pharmaceuticals Inc (Nasdaq:ARDS) stated on Friday that its CEO, Dr Vu Truong, will participate in Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19" to be held on 30 June 2020 at 11:00 ET
The company said it has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening ventilator associated pneumonia (VAP) and preclinical stage antiviral mAbs.
In addition, the company's pipeline also includes AR-701 (COVID-19), a fully human mAb cocktail discovered from convalescent COVID-19 patients that are directed at multiple envelope proteins on SARS-CoV-2. AR-201 (RSV infection). The AR-201 is a fully human IgG1 mAb out-licensed preclinical programme aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review